Etanercept for the treatment of hidradenitis suppurativa

Acta Dermato-Venereologica

Volumn 89, Issue 1, 2009, Pages 82-83

  Sotiriou, Eleni ^a   Apalla, Zoe ^a   Ioannidos, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

ADULT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; LETTER; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SUPPURATIVE HIDRADENITIS; SYMPTOM; TREATMENT DURATION;

ADULT; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58549120005     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0545     Document Type: Letter

References (15)

1. von der Werth JM, Jemec GB. Morbitity in patients with hidradenitis suppurativa. Br J Dermatol 2001; 144: 809-813.
2. Wolkenstein P, Loundou A, Barraou K, Auquier P, Revuz J. Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-623.
3. Jemec GB. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother 2004; 5: 1767-1770.
4. Henderson RL Jr. Treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept. J Drugs Dermatol 2006; 5: 1010-1011.
5. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006; 154: 726-729.
6. Jurgensmayer JC, Fleischer A. Clinical improvement of refractory hidradenitis suppurativa with etanercept. Poster 58. J Am Acad Dermatol 2004; 50 Suppl 3: 15.
7. Zangrilli A, Esposito M, Mio G, Mazzotta A, Chimenti S. Long-term efficacy of etanercept in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2008.
8. Giamarellos-Bourboulis E.J, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008; 158: 567-572.
9. Hurley HJ. Axillary hiperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach. In: Roenigk RA, Roenigk HH Jr, editors. Dermatological surgery: principles and practice. New York: Marcel Dekker, 1989: p. 735.
10. Sartorious K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis supputativa. Br J Dermato 2003; 149: 211-213
11. Ahmed AA, Nordlind K, Schultzberg M, Liden S. Immunohistochemical localization of IL-1 alpha, IL-1 beta, IL-6 and TNF-alpha-like immunoreactivities in human apocrine glands. Arch Dermatol Res 1995; 287: 764-766.
12. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56: 624-628.
13. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Derm Treat 2005; 16: 58-61.
14. Rose R, Goodfield M, Clark S. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin. Clin Exp Dermatol 2005; 31: 154-155.
15. Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, Mouktaroudi M, Spyridaki E, Baziaka F, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 2007; 156: 51-56.